The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold) and Lilly (Silver).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

ASH 2017 | CLARITY: a Phase 2 trial using venetoclax and ibrutinib

Name: CLARITY: a Phase 2 trial using venetoclax and ibrutinib
Uploaded: 2017-12-10T23:10:34.000Z
Duration: 1 min
Description: CLARITY is a Phase II clinical trial studying the combination of ibrutinib and venetoclax in patients with chronic lymphocytic leukemia (CLL). In this video, Francesco Forconi, MD, DM, PhD, FRCPath from the University of Southampton, Southampton, UK discusses the results presented at the American Socienty of Hematology (ASH) 2017 Annual Meeting, held in Atlanta, GA.

Francesco Forconi • 10 Dec 2017

ASH 2017

Chronic Lymphocytic Leukemia Ibrutinib Venetoclax

CLARITY

CLARITY is a Phase II clinical trial studying the combination of ibrutinib and venetoclax in patients with chronic lymphocytic leukemia (CLL). In this video, Francesco Forconi, MD, DM, PhD, FRCPath from the University of Southampton, Southampton, UK discusses the results presented at the American Socienty of Hematology (ASH) 2017 Annual Meeting, held in Atlanta, GA.